Shots:
- Servier has entered into an agreement with Edgewise Therapeutics to acquire its muscular dystrophy business, supporting Servier’s strategic ambition in rare neurology
- As per the deal, Servier will acquire the muscular dystrophy business for ~$2.65B, incl. $1.55B upfront and ~$1.1B in regulatory & commercial milestone payments; closing is expected in Q3’26
- The acquisition adds Edgewise’s capabilities & it’s fast skeletal myosin inhibitor, sevasemten, to Servier’s pipeline. Sevasemten is being evaluated in a pivotal trial cohort for Becker muscular dystrophy & a P-II study for Duchenne muscular dystrophy
Ref: Servier | Image: Edgewise Therapeutics | Press Release
Related News: Servier to Acquire Day One Biopharmaceuticals for ~$2.5B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
